ARCC

ANALYST NOTE: ARCC (Ares Capital Corporation) Date: 2026-06-13 Current Price: $18.03

1. Structural Readiness

• State: Context-Only.
• Conservative Entry: —
• Breakout Level: —
• Extension: —
• ATR Current: 1.8% (Sub-threshold).

2. Thesis Layer

• Thesis Classification: TACTICAL / SETUP-LED.
• Secular Exposure: None.

Analysis: There is no named secular thesis attached to ARCC as of this date. The investment case is not driven by a macroeconomic regime shift or a specific industry-wide secular tailwind identified in the current evidence set. The conviction must be derived entirely from the quality of the business fundamentals, the strength of the management execution, and the tactical readiness of the setup (which is currently absent). We are judging this name on its operational merits and balance sheet strength, not on a pre-existing macro narrative.

3. The Business

Ares Capital Corporation (ARCC) operates as a Business Development Company (BDC) delivering diverse financing solutions predominantly to U.S. middle-market enterprises. The firm invests primarily in first lien senior secured loans, second lien senior secured loans, and unitranche structures, alongside mezzanine debt and selective equity positions.

Key Operational Metrics (as of Q1 2026 / Source Date 2026-04-28):

• Origination Activity: The team originated over $3.2 billion in new investment commitments in the first quarter, with 70% of these transactions coming from existing borrowers, indicating strong client retention and cross-selling capabilities.
• Backlog & Liquidity: The company reported a backlog of approximately $1.8 billion as of the quarter-end, with activity levels in discussions increasing in recent weeks. Available liquidity stands at approximately $6 billion, providing significant advantages in deploying capital.
• Portfolio Quality: The portfolio consists of 607 companies with an average position size of less than 20 basis points, a diversification strategy management states "meaningfully limits idiosyncratic risk." Borrowers generated organic weighted average LTM EBITDA growth of approximately 9% through the end of Q1, which management notes is "in line with ARCC's 10-year average and more than twice the growth rate of the companies within the broader syndicated loan benchmark."
• Deal Terms: New transactions are being discussed at 50 to 75 basis points of enhanced fee and spread levels, alongside a "half to full turn of lower leverage and tighter documentation" compared to the second half of the prior year.
• Financial Performance: Core earnings were $0.47 per share, representing an annualized ROE of 9.6% in a historically slow season for originations. Total investment income was $763.7 million, with interest income (excluding PIK) at $439 million.
• Asset Base: As of December 31, 2025, total assets were approximately $31.2 billion, making ARCC the largest publicly traded BDC by market capitalization at that time.

4. Archetype and Conviction

• Archetype: Quality Compounder.
• Rationale: ARCC fits the "Quality Compounder" archetype due to its consistent ability to generate core earnings, maintain a high-quality, diversified portfolio of middle-market borrowers, and deploy capital at scale with certainty. The evidence highlights a business model that thrives in an environment where commercial banks have de-emphasized middle-market lending (E19, E20), allowing ARCC to capture spread and fee opportunities (E2). The 9% borrower EBITDA growth and 9.6% annualized ROE demonstrate a compounding engine that is resilient to market cycles.
• Valuation Context: The financial spine indicates a forward consensus EPS of $1.91581 for FY1 and $1.92622 for FY2.
• Conviction Stack:
• Thesis Strength: Moderate (Tactical, no macro tailwind).
• Evidence Quality: High (Strong earnings transcript data, clear balance sheet metrics).
• Structural Quality: High (Large cap, diversified, strong liquidity).
• Setup Readiness: Low (No technical setup identified).
• Rerating Potential: Dependent on the continuation of the "certainty of capital" theme and the ability to maintain spread levels as the market evolves.

5. Invalidation, Strengthening, and Gaps

• What Would Strengthen: Confirmation of the "certainty of capital" theme through continued high origination volumes and the ability to maintain or expand the 50-75 bps fee enhancement on new deals.
• Evidence Gaps:
• Specific Sector Exposure: While the profile mentions exposure to technology, healthcare, and manufacturing, the specific weighting of these sectors in the current $31.2 billion portfolio is not detailed in the provided evidence.
• Interest Rate Sensitivity: While SOFR is mentioned in a specific holding (E16), the aggregate sensitivity of the $31.2 billion portfolio to rate changes is not explicitly quantified in the provided text.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Core earnings of $0.47/share with 9.6% annualized ROE; $6 billion available liquidity supporting $1.8 billion backlog; borrower EBITDA growth of 9% outpacing broader syndicated loan benchmark. Sizing hint: Position size should reflect the lack of a technical breakout trigger; treat as a fundamental accumulation rather than a momentum play. Expected path: Management expects to deploy the $6 billion liquidity into the $1.8 billion backlog and new discussions, maintaining fee spreads of 50-75 bps above prior year levels while leveraging the "certainty of capital" advantage. Expected horizon: 12 to 18 months for the fundamental thesis to fully realize through the deployment of the backlog and compounding of earnings. Failure mode to watch: A close below the current price level that coincides with a material reduction in the $6 billion liquidity pool or a failure to originate new commitments at the current fee levels.